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Background: Anemia is a common complication of epidermolysis bullosa (EB). To date, no extensive data on the
prevalence of anemia in EB patients have been well characterized worldwide.
Objective: To determine and to characterize the prevalence of anemia in the Australian EB population by
conducting a retrospective cross-sectional study.
Methods: All (n=368) EB patients registered in the Australasian Epidermolysis Bullosa Registry (AEBR) from 2006
to 2012 were reviewed for pathological evidence of anemia. Patients with EB without anemia and those without
hematological parameters were excluded from the study. Patients’ particulars were separated into pediatric
(b18 years old) and adult (≥18 years old) male and female subgroups.
Results:One-hundred sixty-nine out of 368 EB patients had eligible blood results to be analyzed, as milder
forms of EB did not routinely have laboratory testing; 27.8% (n = 47/169) of EB patients were anemic at
any time point in their lifetime. All generalized severe junctional EB (JEB-GS) cases (100%, n= 4/4); 68.0%
(n = 17/25) of recessive dystrophic EB (RDEB); and 37.5% (n = 6/16) of generalized intermediate JEB
(JEB-I) patients were anemic.
Limitations: As EB is an orphan disease, the limited sample size may have affected the signiﬁcance of the
study result.
Conclusion: The high prevalence of anemia seen in RDEB and JEB generalized severe (JEB-GS) patients in our
cohort is similar to those reported in case series.
© 2014The Authors. Published by Elsevier Inc. on behalf ofWomen's Dermatologic Society. This is an open access
article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/4.0/).Introduction
Epidermolysisbullosa (EB) is aheterogeneousgroupof genodermatoses,
which affects the skin,mucousmembranes, and sometimes, internal or-
gans. It is characterized by cutaneous blistering, bullae, and erosions
that result from slight mechanical trauma and impaired wound healing
(Haber et al., 1985; Kuo et al., 2006;Mitsuhashi & Hashimoto, 2003). EB
is a rare disease with a reported prevalence of all dominant types to-
gether estimated to be at 1:50,000 and the recessive forms to be
1:300,000 (Kuo et al., 2006). Patients may develop a host of complica-
tions, from skin infections, to skin cancers, anemia, and renal failure,
to mention a few with high mortality. EB has no sex predilection and
occurs worldwide. The prevalence is estimated to be approximately
8.22 per million in the United States (Fine & Hintner, 2009) and 12.78
per million in Australia (Kho et al., 2010).
Fourmajor types of EB are recognized following the Third and Fourth
International Consensus Meeting on Diagnosis and Classiﬁcation of EB:
EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), and Kindler
syndrome (Fine et al., 2008, 2014; Samad et al., 2004). The classiﬁcation.
er Inc. on behalf of Women's Deris based on the main clinical features and differences in the ultra-
structural level within which blisters develop in EB skin (Fine et al.,
2008; Mitsuhashi & Hashimoto, 2003; Samad et al., 2004). In this
study, major types of EB have been further divided into major subtypes
of EB as characterized in [5]. These are EBS, JEB-GS, JEB-I, dominant dys-
trophic EB (DDEB), recessive DEB (RDEB), and Kindler syndrome (Fine
et al., 2008, 2014).
Anemia commonly occurs in patients with severe types of EB, parti-
cularly in RDEB and JEB, but also to a lesser extent in some other sub-
types (Antunes et al., 1999). Patients with RDEB often present with
severe anemia, becoming dependent on multiple blood transfusions
(Antunes et al., 1999; Fine & Hintner, 2009).
Although anemia in EB patients is a well-known entity, no epidemi-
ological studies had been previously conducted worldwide to show as-
sociations that exist between anemia and subtypes of EB. Therefore, this
study will be the ﬁrst retrospective cross-sectional study that addresses
this correlation in the Australian EB population.
We report the prevalence of anemia in major subtypes of EB in both
pediatric and adult EB populations living in Australia, any gender diffe-
rence, and themeanhemoglobin value in different EB subtypes.We also
recommend directions to future studies with regard to early screening
and prompt treatment of anemia in EB patients.matologic Society. This is an open access article under the CC BY-NC-SA license
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Ethics statement
This study was a part of a project with ethics approval, “Develop-
ment of an EB registry including rates of complications and severity of
symptoms in EB patients within Australasia.” In August 2006, the ethics
approval for the projectwas granted from the South Eastern Sydney and
Illawarra Area Health Service Human Research Ethics Committee (refe-
rence number 06/89). The project was also approved by the Bellberry
Ethics Committee. (201202-683, 2012) and by the University of New
South Wales ethics committee in January 2010.Study population
Patients with subtypes of EB were diagnosed by EB expert dermato-
logists across Australia based on clinical assessment, light microscopic
examination of a skin biopsy, immunoﬂuorescence antigenic mapping,
and transmission electron microscopy (Fine & Mellerio, 2009). Patients
from the Australasian Epidermolysis Bullosa Registry (AEBR) in the pe-
riod 2006–2012 were included in the study. The AEBR was established
on November 8, 2006, at St George Hospital in Sydney (Kho et al.,
2010). The patientswith EB belonging to a non-proﬁt national organiza-
tion, Dystrophic Epidermolysis Bullosa Research Association (DebRA)
Australia were also eligible.
Informed consents were obtained from EB patients registered in
AEBR to participate in the study. The studywas conducted by reviewing
all consenting patients’ medical records and by contacting pathology
laboratories where applicable across Australia; general practitioners
were contacted for pathology results when necessary.
Patients without blood test results, incomplete data sets in ﬁles, and
insufﬁcient pathology results were excluded from the study. Of the 368
patients registered in AEBR by the end of 2012; 199 patients had no
blood test results available for various reasons. These include patients
with milder forms of EB such as EBS, who never had any blood tests
taken unless indicated for other health concerns; some patients with
JEB-GS subtype had died without blood having been taken; and some
patients’ contact details along with general practitioners’ had changed
so they were not contactable.Table 1
Basic characteristics of EB patients in the study.









EBS 80 (47.3%)Study-outcome deﬁnitions
In the study, patients were also separated into pediatric (b18 years
old) and adult (≥18 years old) subgroups. In the pediatric group,
anemia was deﬁned as hemoglobin of less than 11 g/dL. In adults, ane-
mia is deﬁned as hemoglobin below 13 g/dL in men or 12 g/dL in
women (Moreno Chulilla et al., 2009). The pathological evidence of a
decrease mean in hemoglobin levels from a reference range was deﬁned
based on age and sex (Janus & Moerschel, 2010; Moreno Chulilla et al.,
2009; Tefferi, 2003). Anemic patients were further classiﬁed into macro-
cytic (MCV N98 fL), normocytic (MCV = 82–98) and microcytic (MCV
b82 fL) categories based on the MCV (Mean Corpuscular Volume) (Janus








EB, epidermolysis bullosa; EBS, epidermolysis bullosa simplex; DDEB, dominant dystro-
phic epidermolysis bullosa; RDEB, recessive dystrophic epidermolysis bullosa; JEB-nH,
junctional epidermolysis bullosa –non-Herlitz, newly known as generalized intermediate;
JEB–Herlitz, junctional epidermolysis bullosa – Herlitz, newly known as JEB generalized
severe; KS, Kindler syndrome.Data collection and analysis
Data were collected according to standardized criteria. The informa-
tion gathered fromall subjects included; the age, gender, diagnosis of EB
subtypes with conﬁrmed histopathological evidence, and cross section-
al values of hemoglobin in their lifetime as severe forms of EB patients
die at early age. Data collections and statistical analysis of hemoglobin
levels were also conducted using SPSS software version 16.0.1 (SPSS
Inc, Chicago, Illinois) and Microsoft Excel program.Results
Demographics
Of the 169 patients included in the analysis, the sex distribution was
similar, with 76 males (44.9%) and 93 females (55.0%). Patient age
ranged from 3 days to 99 years, with mean age of 29.2 years (Table 1).
Hemoglobin ranged from 2.7 g/dL to 20.2 g/dL, with mean hemoglobin
of 12.65 g/dL.Most of the patients in the study population had EBS (n=
80), DDEB (n=43), RDEB (n=25), JEB-I (n=16), JEB-GS (n=4) and
KS (n= 1).
Hemoglobin levels in EB patients
The mean hemoglobin level for pediatric patients (n = 62) was
12.14 ± 3.02 g/dL, for adult male patients (n = 41) was 13.57 ±
2.29 g/dL, for adult female patients (n = 66) was 12.56 ± 2.01 g/dL.
The mean hemoglobin level was 13.49 ± 1.62 g/dl in EBS, 12.87 ±
2.49 g/dL in DDEB, 10.19 ± 3.08g/dL in RDEB, 12.62 ± 2.53g/dL in JEB-I
group and 8.55 ± 1.29g/dL in JEB-GS group. Fig. 1 describes the mean
hemoglobin level in different subtypes of EB.
One-way ANOVA (F, 11.5; F critical value, 2.3), comparing hemo-
globin levels among different subtypes of EB, suggests that the
differences in mean hemoglobin values in different subtypes of EB
are statistically signiﬁcant.
Prevalence of anemia among adult men and women with EB, and in
pediatric EB patients
Among the 169 patients, 47 (27.8%) had anemia. Among 41 male
adult patients, 13 (31.7%) had anemia; among 66 female adult patients,
18 (27.3 %) had anemia; among 62 pediatric patients, 16 (25.8%) had
anemia. The prevalence of anemia did not differ signiﬁcantly according
to sex in adult groups (p = .369, chi-test), however the prevalence of
anemia among adults were higher than those among pediatric patients
(p= .029, chi-test).
Prevalence of anemia in subtypes of EB
The overall prevalence of anemia in DDEB patients (n = 43) was









EBS DDEB RDEB JEB-nH JEB-H
Mean Haemoglobin in EB subtypes
Mean Hb g/l
Fig. 1.Mean haemoglobin level in different subtypes of EB.
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in pediatric,male adults and female adultswere 23.5% (n=4/17), 50.0%
(n= 4/8) and 16.7% (n= 3/18) respectively.
The overall prevalence of anemia in EBS patients (n= 80) was 11.3%
(n = 9/80). Among 80 EBS patients, 25 were pediatric, 21 were male
adults, and 34 were female adults. The prevalence of anemia in pediatric,
male adults and female adults were 4.0% (n= 1/25), 14.3% (n= 3/21)
and 14.7% (n= 5/34) respectively.
The overall prevalence of anemia in JEB-I patients (n = 16) was
37.5% (n = 6/16). Among 16 JEB-I patients, 9 were pediatric, 4 were
male adults, and 3 were female adults. The prevalence of anemia in pe-
diatric patients, male adults, and female adults were 22.2% (n = 2/9),
50.0% (n= 2/4) and 66.7% (n= 2/3) respectively.
The overall prevalence of anemia in RDEB patients (n = 25) was
68.0% (n= 17/25). Among 25 RDEB patients, 7 were pediatric, 7 were
male adults, and 11 were female adults. The prevalence of anemia in pe-
diatric patients, male adults, and female adults were 71.4% (n = 5/7),
57.1% (n = 4/7) and 72.7% (n = 8/11) respectively. Of these, 22/25
were known to be receiving intermittent iron or blood transfusions
whichwould elevate the average hemoglobin level. Twoof these patients
had thalassemia trait uncovered on transition to the adult EB center; iron
infusions were therefore ceased and changed to blood transfusions.
The overall prevalence of anemia in JEB-GS patients (n = 4) was
100.0% (n = 4/4). There were only pediatric patients in this subtype,
as the mortality is very high at a young age.
There was only one patient with KS in the study population and he
was not anemic.Discussion
To our knowledge, this is the ﬁrst descriptive study that presents the
epidemiologic data on anemia in all major subtypes of EB patients.
Although several studies have described anemia as one of common
complications encountered in severe forms of EB (Van den Akker et al.,
2009), no epidemiologic data on anemia in all subtypes of EB patients
from an adequate sized cohort has been published for statistical evi-
dence. Such data have been collated from AEBR and analysed leaving
statistical grounds for future researches on the topic of anemia.
In our study, the overall prevalence of anemia among EB patients
(27.8%) was higher than the general population. According to the
Australian Bureau of Statistics, in the Australian general population
between 2011 and 2012, 4.5% of the adult population was at risk of
anemia (Australian Bureau Statistics, 2013). Hence ourﬁndings indicate
the necessity of routine hematological parameter monitoring in EB
patients in general.Anemia is commonly observed in more severe forms of EB, notably
RDEB and JEB (Kho et al., 2010). This is similarly demonstrated in our
study as the top three most prevalent anemic EB subtypes were JEB-
GS (100.0%), RDEB (68.0%), and JEB-I (37.5%). Thus, this constitutes fur-
ther evidence of the need for more closely monitoring hematological
parameters of EB patients routinely in the severe forms than non-
severe subtypes of EB to ensure that mortality and morbidity are mini-
mized and quality of life are optimized.
Variable degrees of anemia occur in different subtypes of EB. Com-
prehensive literature search review by Fine and Mellerio (2009) sug-
gests that a hemoglobin level of 8g/dL was maintained in severe forms
of EB despite iron supplements. This literature suggestion ﬁts with our
ﬁndings that some of the most severely affected EB patients demon-
strated mean hemoglobin levels of 8.55 ± 1.29g/dL and 10.19 ±
3.08g/dL in JEB-GS and RDEB respectively.
Inmore severe forms of EB, such as RDEB and JEB-GS; the prevalence
of anemia was higher or similar in pediatric group compared to the
adult groups. This ﬁnding was contrasting in mildly affected types of
EB, such as EBS and JEB-I; in which adult group’s prevalence of anemia
was higher than pediatric group. This suggests that chronic blood loss
from the skin and mucosae in milder forms of EB may result in anemia
later and hence, anemia should be checked for in adultswith EBS aswell
as JEB-I.
In most EB patients, anemia is known to be multifactorial in origin,
one of the causes being anemia of chronic disease (Fine & Hintner,
2009). Other factors contributing to anemia include chronic blood,
iron, and protein loss from open wounds on the skin, and through ero-
sions present within the intestinal tract (mouth, esophagus, and anal
canal), and poor intake and absorption of iron and other nutrients lead-
ing to iron deﬁciency (Van denAkker et al., 2009). Another known cause
of anemia in EB patient is from chronic inﬂammation from persistently
open wounds and skin ulcerations leading to repeated skin infections,
resulting in a blunted bone marrow response to the elevated levels of
erythropoietin (Clark, 2009; Fine & Hintner, 2009; Tefferi, 2004).
Hence, the anemia is an additional co-morbidity of this severe der-
matologic disorder (Fine et al., 2008). Therefore, it is important to iden-
tify and treat anemia as optimally as possible in EB patients to reduce
the morbidity of the patients.
Our study ﬁndings are consistent with several published smaller re-
views and case-series, which all indicate anemia is prevalent in EB pa-
tients [8,10,13,20]. 54% of JEB-GS patients in a small longitudinal
retrospective study (n= 22) performed in Netherlands were reported
to have anemia as one complication, without going into details as to se-
verity [20]. Similarly, prevalence of anemia in this group was signiﬁ-
cantly high, as 100% of JEB-GS patients in our study were anemic. It
may be possible to conclude that the signiﬁcance of our study’s result
may be limited due to missing data, mainly from the milder patients;
however our study’s sample is representative of population. For in-
stance, the general consensus is that patientswith JEB-GSdonot survive
to adulthood. JEB-GS cohorts in Australia (n = 11) (Kho et al., 2010)
showed a 100% mortality in childhood, with patients not surviving
past 13 months.
Hubbard et al. (Hubbard et al., 2011) found that 96% (n=52/54) of
pediatric RDEB patients were anemic in a cross-sectional study con-
ducted in a multidisciplinary team study day in London. This study
was limited to more severe patients already seeing a dietician and mul-
tidisciplinary team. This ﬁnding is similarly presented in our study ﬁnd-
ing as 71.4% of pediatric RDEB patients were found to be anemic;
possibly the prevalence in our groupwas less as it included somemilder
cases of localized RDEB.
Based on the results of our study and in accordance with the litera-
ture on this topic, we conclude that anemia is prevalent among EB pa-
tients, and is highly prevalent in patients with severe forms of EB.
Some limitations to our study should be noted; potential sample
selection bias may have affected the ﬁndings. The study population
is not representative of the entire EB population in Australia. This
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refusal to be registered in the AEBR and loss of follow up. Second,
the prevalence of anemia may have been overestimated in some EB
subtypes, such as EBS, as healthy patients may not have been re-
quired to take bloods in their lifetime. Whereas, in severe forms of
EB such as RDEB, the prevalence of anemia may have been
underestimated as RDEB patients are often being treated with
blood and iron transfusions, which elevate their hemoglobin. Third,
the design of the study was observational and cross-sectional. We
were able to examine potential association but were unable to mea-
sure causation. Fourth, the data which allow the classiﬁcation of the
causes of anemia such as reticulocyte counts, erythropoietin levels,
and iron studies were not measured as the study was retrospective
and these values were not available in all patients. Moreover, due
to the rare nature of the disease and high mortality in severe forms
of EB such as JEB-GS, the limited number of patients may have affect-
ed the power of the study.
Overall, such profound anemia certainly contributes to chronic
fatigue, reduced energy levels, dyspnea, reduced exercise tolerance, im-
paired wound healing, and anorexia, thereby decreasing patients’ qua-
lity of life (Fine & Hintner, 2009; Fridge & Vichinsky, 1998). These
patients often require frequent blood transfusions to correct their ane-
mia to a level that reduces clinical symptoms (Fine et al., 2008). Current-
ly, there are no international recommendations or consensus on
treatment for these anemic EB patients. As this study included a rela-
tively large number of EB patients given that EB is a rare orphan disease,
looking at the degree of anemia; it will form an epidemiological founda-
tion for future studies on this diverse topic of anemia in EB and treat-
ment options.
We also recommend the development of a standardised protocol for
the evaluation of anemia in both pediatric and adult EB patients, in par-
ticular for severe forms of EB in order to facilitate early intervention if
required. We would recommend that each EB patient have screening
for anaemia and a baseline of their renal function at diagnosis, since
chronic blood loss from the blisteringmay already show reduced hemo-
globin. If reduced, iron studies should be performed. Mild patients with
EBS should have their hemoglobin checked every 2 years after puberty,
as it appears from this data that a proportion of the milder patients de-
velop anaemia as adults. Severe EB patients should be having their
blood screened every 3 to 6 months, as recommended by Martinez
(Martinez, 2010). Before iron infusions are given, some patients with
Asian or Mediterranean ancestry should be screened for thalassemia
trait, as this is relatively common in those populations, and they can
develop iron overload from iron rather than whole blood infusions. A
descriptive epidemiological study of anemia in EB population in other
countries to correlate ﬁndings from our study may be helpful for future
management of anemia in EB patients.Acknowledgments
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